Literature DB >> 18594870

Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children.

Anna M Wasilewska1, Walentyna M Zoch-Zwierz.   

Abstract

The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS). The study group (1) consisted of 18 children SDNS aged 3.5-17.0 years treated with CyA. All NS children were examined three times: (A) at proteinuria relapse, before CyA treatment, (B) after 6 months, and (C) after 12 months of CyA administration. The control group (2) consisted of 18 healthy children. Serum CyA level was assessed by immunofluorescence. Enzyme-linked immunosorbent assay kits for total human MMP2 and 9 and TIMP1 and 2 were obtained from R&amp;D Systems. Compared with healthy controls, urinary MMP9/Cr in NS children before CyA was on the same level and increased during CyA treatment, and urinary TIMP1/Cr was twice as high and increased significantly during CyA treatment. MMP9/TIMP1 in NS children treated with CyA increased, but the difference was not statistically significant. Urinary MMP2/Cr was similar, and urinary TIMP2/Cr was significantly higher in children treated with CyA (p < 0.01). The MMP2/TIMP2 ratio in NS children treated with CyA was significantly lower in comparison with healthy controls (p < 0.01). A negative correlation was noted between urinary MMP2/TIMP2 ratio and serum CyA in NS children (r = -0.541, p < 0.01). An imbalance within the MMP2 and TIMP2 and MMP9 and TIMP1 system may play a role in the pathogenesis CyA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594870     DOI: 10.1007/s00467-008-0881-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  40 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 2.  Smad proteins and transforming growth factor-beta signaling.

Authors:  M Schiffer; G von Gersdorff; M Bitzer; K Susztak; E P Böttinger
Journal:  Kidney Int Suppl       Date:  2000-09       Impact factor: 10.545

3.  Cyclosporine A-induced arteriolopathy.

Authors:  T T Antonovych; S G Sabnis; H A Austin; A G Palestine; J E Balow; R B Nussenblatt; G B Helfrich; M L Foegh; M R Alijani
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

Review 4.  Matrix metalloproteinases and cardiovascular disease.

Authors:  C M Dollery; J R McEwan; A M Henney
Journal:  Circ Res       Date:  1995-11       Impact factor: 17.367

5.  Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts.

Authors:  M Ruiz-Ortega; J Egido
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

6.  Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease.

Authors:  Jan Henrik Hörstrup; Mathias Gehrmann; Birgit Schneider; Angela Plöger; Peter Froese; Thea Schirop; Dieter Kampf; Ulrich Frei; Rainer Neumann; Kai-Uwe Eckardt
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

7.  Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells.

Authors:  Tara McMorrow; Michelle M Gaffney; Craig Slattery; Eric Campbell; Michael P Ryan
Journal:  Nephrol Dial Transplant       Date:  2005-07-19       Impact factor: 5.992

8.  Abnormalities of the extracellular degradation of collagen type I in essential hypertension.

Authors:  C Laviades; N Varo; J Fernández; G Mayor; M J Gil; I Monreal; J Díez
Journal:  Circulation       Date:  1998-08-11       Impact factor: 29.690

Review 9.  Chronic cyclosporine nephrotoxicity.

Authors:  T F Andoh; W M Bennett
Journal:  Curr Opin Nephrol Hypertens       Date:  1998-05       Impact factor: 2.894

10.  Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.

Authors:  K Akiyama; K Shikata; H Sugimoto; M Matsuda; Y Shikata; N Fujimoto; K Obata; H Matsui; H Makino
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1997-02
View more
  5 in total

1.  Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis.

Authors:  Kimberly A Czech; Michael Bennett; Prasad Devarajan
Journal:  Pediatr Nephrol       Date:  2011-07-01       Impact factor: 3.714

2.  Performance of novel kidney biomarkers in preclinical toxicity studies.

Authors:  Dana Hoffmann; Melanie Adler; Vishal S Vaidya; Eva Rached; Laoighse Mulrane; William M Gallagher; John J Callanan; Jean C Gautier; Katja Matheis; Frank Staedtler; Frank Dieterle; Arnd Brandenburg; Alexandra Sposny; Philip Hewitt; Heidrun Ellinger-Ziegelbauer; Joseph V Bonventre; Wolfgang Dekant; Angela Mally
Journal:  Toxicol Sci       Date:  2010-01-29       Impact factor: 4.849

3.  Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity.

Authors:  Max Sieber; Dana Hoffmann; Melanie Adler; Vishal S Vaidya; Matthew Clement; Joseph V Bonventre; Nadine Zidek; Eva Rached; Alexander Amberg; John J Callanan; Wolfgang Dekant; Angela Mally
Journal:  Toxicol Sci       Date:  2009-04-06       Impact factor: 4.849

4.  Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics.

Authors:  Shipra Agrawal; Michael L Merchant; Jiro Kino; Ming Li; Daniel W Wilkey; Adam E Gaweda; Michael E Brier; Melinda A Chanley; Jessica R Gooding; Susan J Sumner; Jon B Klein; William E Smoyer
Journal:  Kidney Int Rep       Date:  2019-09-19

5.  Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury.

Authors:  Jens H Westhoff; Burkhard Tönshoff; Sina Waldherr; Johannes Pöschl; Ulrike Teufel; Timm H Westhoff; Alexander Fichtner
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.